The eIF2α inhibitor GSK2606414 can reduce eIF2α expression and alleviate PASMC proliferation, suggesting a novel regulatory mechanism where m6A modification of eIF2α plays a critical role in PAH pathogenesis [190]. This evidence concerns the gene EIF2A and pulmonary arterial hypertension.